Detalles de la búsqueda
1.
Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
Breast Cancer Res Treat
; 161(1): 73-81, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27807808
2.
HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.
Eur J Cancer Care (Engl)
; 26(2)2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26503126
3.
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Ann Oncol
; 27(7): 1249-56, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27052654
4.
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.
Ann Oncol
; 26(2): 422-8, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25403589
5.
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
Ann Oncol
; 26(5): 1005-1011, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25646368
6.
Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.
Ann Oncol
; 25(8): 1563-70, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24827132
7.
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
Ann Oncol
; 25(6): 1128-36, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24618153
8.
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.
Invest New Drugs
; 31(3): 724-33, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22996801
9.
Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study.
Eur J Cancer Care (Engl)
; 22(5): 638-47, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23647444
10.
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.
Br J Cancer
; 106(4): 673-7, 2012 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22240778
11.
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
Br J Cancer
; 107(4): 598-603, 2012 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-22790797
12.
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.
Ann Oncol
; 23(10): 2572-2577, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22499859
13.
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.
Ann Oncol
; 23(3): 610-617, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21700731
14.
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
Ann Oncol
; 23(10): 2552-2561, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22431701
15.
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.
Br J Cancer
; 105(3): 366-71, 2011 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-21750556
16.
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.
Br J Cancer
; 105(10): 1480-6, 2011 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-22009030
17.
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.
ESMO Open
; 6(3): 100134, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33984676
18.
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.
Br J Cancer
; 103(9): 1335-42, 2010 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-20978512
19.
Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study.
Ann Oncol
; 21(7): 1448-1454, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20038515
20.
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.
Br J Cancer
; 101(8): 1357-64, 2009 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19755993